Clinical Oncology and Cancer Research最新文献_第10页

Research progress on the effect of anesthesia on anthracycline cardiotoxicity 麻醉对蒽环类药物心脏毒性影响的研究进展

Clinical Oncology and Cancer Research Pub Date : 2013-12-01 DOI: 10.3969/J.ISSN.1000-8179.20131076

Hongwei Zhao, Jingcheng Li

{"title":"Research progress on the effect of anesthesia on anthracycline cardiotoxicity","authors":"Hongwei Zhao, Jingcheng Li","doi":"10.3969/J.ISSN.1000-8179.20131076","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131076","url":null,"abstract":"Anthracycline-based antitumor drugs are one of the highly effective broad-spectrum anti-cancer drugs that are commonly used clinically. However, anthracyclines have the serious side effect of cumulative dose-related cardiotoxicity. Clinically, intake of myocardial protective drugs is one of the most important strategies for the safe use of anthracyclines in chemotherapy. Numerous cancer patients un- dergoing chemotherapy also require surgery, during which general anesthesia is commonly used. Various studies have shown that propofol and sevoflurane, the most commonly used general anesthetics, present a significant protective effect in myocardial ischemia-reperfusion damage. Therefore, for patients who have just undergone chemotherapy with anthracyclines, anthracycline-induced myocardial injury may occur at the acute or chronic phase of surgery. Consequently, if the effect of anesthetics on the cardiotoxicity of anthracyclines is similar to the protective effect of these drugs for myocardial ischemia-reperfusion damage, this protective effect on cardiotoxicity will have significant impact on the recovery of cardiopulmonary function of patients after surgery. Thus, further studies are needed to establish the effect of anesthetics on the cardiotoxicity of anthracyclines.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2013-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114801018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-disciplinary diagnosis and treatment of a malignant pheochromocytoma with multiple metastases 恶性嗜铬细胞瘤多发转移的多学科诊断与治疗

Clinical Oncology and Cancer Research Pub Date : 2013-11-15 DOI: 10.3969/J.ISSN.1000-8179.20131397

Ya-wen Zheng, Xinwei Zhang, Z. Zhan, Zhaoxiang Ye, Wengui Xu, P. Wang, Zhi Guo, X. Yao, G. Xie, Dingzhi Huang, X. Ren

{"title":"Multi-disciplinary diagnosis and treatment of a malignant pheochromocytoma with multiple metastases","authors":"Ya-wen Zheng, Xinwei Zhang, Z. Zhan, Zhaoxiang Ye, Wengui Xu, P. Wang, Zhi Guo, X. Yao, G. Xie, Dingzhi Huang, X. Ren","doi":"10.3969/J.ISSN.1000-8179.20131397","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131397","url":null,"abstract":"9 Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China Abstract Malignant pheochromocytomas are rare tumors that arise from chromaffin tissue, and the diagnostic criterion of malig- nancy is based on the development of metastases. In the case a patient suffers the tumor with liver, lung and bone metastases. However, the test results of tumor markers, gastroscopy, chest and abdominal CT, and PET-CT examination are hard to make a definite diagnosis. The patient was finally diagnosed with malignant pheochromocytoma with liver, lung and bone metastases following the needle biopsy of liver and underwent the excision of a right adrenal pheochromocytoma. Therapeutic standard for the malignant pheochromocytomas is not available so far. It is reported that chemotherapeutic CVD regimen (cyclophosphamide, vincristine, and daecarbazine) and suni- tinib may be effectual in the alike cases. The patient received two cycles of CVD and one cycle of sunitinib, nevertheless, slow progres- sion of the disease remained after the treatment. The results of multi-disciplinary treatment have suggested that 131I-MIBG may just be a choice for this patient.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2013-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122909067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cisplatin-induced up-regulation and enrichment of BCRP and EHD2 on cell surface 顺铂诱导BCRP和EHD2在细胞表面的上调和富集

Clinical Oncology and Cancer Research Pub Date : 2013-11-15 DOI: 10.3969/J.ISSN.1000-8179.20131427

Pan Li, L. Pan, Xin Fu, Shaobin Yang, Jingwen Feng, Mingqiu Hu, G. Ying

引用次数: 0

Clinical significance of neutrophil and albumin pretreatments in nasopharyngeal carcinoma prognosis 中性粒细胞和白蛋白预处理对鼻咽癌预后的临床意义

Clinical Oncology and Cancer Research Pub Date : 2013-11-15 DOI: 10.3969/J.ISSN.1000-8179.20130875

Xiaofeng Tang, Lin Zhang, Jiang Li

{"title":"Clinical significance of neutrophil and albumin pretreatments in nasopharyngeal carcinoma prognosis","authors":"Xiaofeng Tang, Lin Zhang, Jiang Li","doi":"10.3969/J.ISSN.1000-8179.20130875","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20130875","url":null,"abstract":"Objective: To investigate the association of pretherapeutic neutrophil, lymphocyte, monocyte, and serum albumin levels with nasopharyngeal carcinoma (NPC) prognosis in 401 patients. Methods: This study involved 401 NPC patients recently diagnosed and admitted in Sun Yat-sen University Cancer Center, China. Laboratory variables, such as immunology-related parameters and albumin level prior to treatment, were analyzed. The overall survival and disease-free survival rates were determined using the Kaplan-Meier method and were then compared using the log-rank test. Univariate and multivariate analyses were performed using the Cox proportional hazards model to identify prognostic factors. Results: Patients with neutrophil counts >5.20×10/L (n=172) had significantly lower overall survival and disease-free survival rates compared with those with neutrophil counts≤5.20×10/L (n=229) (P=0.014, P=0.009). In the 401 NPC cases, patients with high albumin levels (>43.00 g/L; n=253) had significantly higher overall survival (P=0.000) and disease-free survival (P=0.006) rates compared with those with low albumin levels (≤43.00 g/L; n=148). Multivariate analysis showed that the neutrophil level is an independent risk factor for disease-free survival, whereas the albumin level is a strong independent prognostic factor for overall survival. Conclusion: The pretherapeutic neutrophil and albumin levels are independent prognostic factors for survival in NPC patients.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"61 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2013-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121384505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics and treatment of primary ovarian malignant lymphoma 原发性卵巢恶性淋巴瘤的临床特点及治疗

Clinical Oncology and Cancer Research Pub Date : 2013-11-15 DOI: 10.3969/J.ISSN.1000-8179.20131689

J. Zhao, Hua-qing Wang, Ping Wang

{"title":"Clinical characteristics and treatment of primary ovarian malignant lymphoma","authors":"J. Zhao, Hua-qing Wang, Ping Wang","doi":"10.3969/J.ISSN.1000-8179.20131689","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131689","url":null,"abstract":"Objective: To investigate the clinical features and prognostic factors of primary ovarian lymphoma(POL). Methods: A retrospective review was performed based on the clinical records of 14 POL cases treated at Tianjin Medical University Oncology institute Hospital verity from 2000-6 to 2010-5. Results: The median age of patients was 47 years at presentation(range 28~62years). Abdominal pain was the most common initial symptom. The majority of histological subtype was B cell lymphoma, above 50% of which is diffuse large B-cell non-Hodgkin's lymphoma. A R0 resection was carried out in 2 patients who were lost to follow-up soon after surgery. 11 patients were treated by CHOP, FC or CHOPE chemotherapy. Chemotherapy combined with rituximab were given to 5 patients. Until now, 5 patients were alive, 6 patients died, and only one patient was lost to follow up after therapy. Conclusion: POL is an extremely rare lymphoma. The ultimate diagnosis depends on histopathologic examination. Primary ovarian non-Hodgkin lymphoma should be treated with multi-modality strategies. Treatment with doxorubicin-based chemotherapy after oophorotomy is recommended. B cell lymphoma preferred to use rituximab combination chemotherapy. Abdominal cavity chemotherapy prophylaxis and irradiation can decrease the probability for recurrence .","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"27 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2013-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132914320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Identifying the genetic pattern of conventional fractionated and hypofractionated radiotherapy using whole genome expression microarray in a non-small-cell lung cancer cell line 利用全基因组表达芯片在非小细胞肺癌细胞系中鉴定传统分割和低分割放疗的遗传模式

Clinical Oncology and Cancer Research Pub Date : 2013-11-15 DOI: 10.3969/J.ISSN.1000-8179.20121843

Jian Sun, Ningbo Liu, C. Qu, Baohu Wang, Hua Guo, Ping Wang

引用次数: 0

Research progress in molecular targeted therapy for gynecological cancer 妇科肿瘤分子靶向治疗研究进展

Clinical Oncology and Cancer Research Pub Date : 2013-11-15 DOI: 10.3969/J.ISSN.1000-8179.20130819

Huijuan Wu, Q. Hao

引用次数: 0

Clinical features and prognostic analysis of breast angiosarcoma 乳腺血管肉瘤的临床特点及预后分析

Clinical Oncology and Cancer Research Pub Date : 2013-10-30 DOI: 10.3969/J.ISSN.1000-8179.20130902

Hui Xu, Mu Yang, Yongsheng Jia, Z. Tong

引用次数: 0

Effect of hypofractionated palliative thoracic radiotherapy for advanced non-small cell lung cancer 低分割胸部姑息性放疗治疗晚期非小细胞肺癌的效果

Clinical Oncology and Cancer Research Pub Date : 2013-10-30 DOI: 10.3969/J.ISSN.1000-8179.20131579

Weishuai Liu, Lujun Zhao, Zhiyan Liu, Bo-ai Li, Z. Yuan, Ping Wang

{"title":"Effect of hypofractionated palliative thoracic radiotherapy for advanced non-small cell lung cancer","authors":"Weishuai Liu, Lujun Zhao, Zhiyan Liu, Bo-ai Li, Z. Yuan, Ping Wang","doi":"10.3969/J.ISSN.1000-8179.20131579","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131579","url":null,"abstract":"Objective: To investigate the effect and toxicity of short-course and hypofractionated palliative thoracic radiotherapy (PTR) for advanced non-small cell lung cancer (NSCLC). Methods: A total of 25 patients with stageIIIB and stageIV NSCLC, who underwent PTR from September 2010 to July 2006, were retrospectively analyzed. The PTR regime was 45 Gy in 15 fractions. Symptom relief, effect, and toxicity after completion of PTR were assessed. Survival was analyzed using the Kaplan-Meier method. Results: Except for one patient who completed only 36 Gy in 12 fractions, all other patients completed all plans. The thoracic symptoms of 18 patients were relieved. The response rates for the five main symptoms were: hemoptysis 87.5% (7/8), cough 70.6% (12/17), pain 73.3% (11/15), dyspnea 57.1% (8/14), and hoarseness 50% (1/2). The complete response and partial response after PTR was 28%, and no grade 3 or higher toxicities occurred. The median time of overall survival (OS) is 13 months (95% CI: 6.6 months to 19.5 months), and one-year OS is 51.5%. According to the univariate analysis, KPS before PTR, the number of post-PTR was significantly related to the survival. Conclusion: For advanced NSCLC patients, the PTR regime given as 45 Gy in 15 fractions evidently relieved thoracic symptoms, improved OS, and shortened treatment time. Recent relevant adverse radiotherapy reactions are low, and more prospective clinical studies must be conducted.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2013-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128838178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacokinetic study of palonosetron hydrochloride in healthy volunteers 盐酸帕洛诺司琼在健康人体的药动学研究

Clinical Oncology and Cancer Research Pub Date : 2013-10-30 DOI: 10.3969/J.ISSN.1000-8179.20131398

Zhongling Zhu, Zhongsheng Tong, Duan-yun Si, Weilin Dong, Zhao Yan

{"title":"Pharmacokinetic study of palonosetron hydrochloride in healthy volunteers","authors":"Zhongling Zhu, Zhongsheng Tong, Duan-yun Si, Weilin Dong, Zhao Yan","doi":"10.3969/J.ISSN.1000-8179.20131398","DOIUrl":"https://doi.org/10.3969/J.ISSN.1000-8179.20131398","url":null,"abstract":"Objective: To evaluate the pharmacokinetics of palonosetron hydrochloride in healthy volunteers. Methods: Thirty-one healthy volunteers were grouped into three palonosetron hydrochloride dosage regimens of 0.125, 0.25, and 0.5 mg. The plasma concentrations of palonosetron were determined by ultra high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). DAS 2.1 software was applied to assess the plasma concentration-time data. Results: After intravenous injection of 0.125, 0.25, and 0.5 mg palonosetron to the subjects, the AUC0-168h values of palonosetron were (7.5±2.5), (15.2±4.0), and (34.8±9.7) μg· h·mL. The t1/2 values were (27.2±9.5), ( 27.2±6.5), and (31.4±5.6) h. Palonosetron exposure increased proportionally with the dose range of 0.125 mg to 0.5 mg. The correlation coefficient was 0.998. No grade 3 or grade 4 toxicity was observed during the study. Conclusion: A rapid, sensitive, and selective UPLC-MS/MS method for palonosetron quantification in human plasma was developed and validated. All the participants indicated high tolerance throughout the study. Our data showed that palonosetron exhibits linear pharmacokinetics over the the dose range of 0.125 mg to 0.5 mg.","PeriodicalId":314105,"journal":{"name":"Clinical Oncology and Cancer Research","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2013-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115630366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0